Skip to main content
Premium Trial:

Request an Annual Quote

Cequent Begins Long-Term Tox Study with FAP Drug

Premium

Cequent Pharmaceutials said this week that it has begun a long-term toxicology study of its preclinical treatment for familial adenomatous polyposis, dubbed CEQ508.

The drug, which is based on Cequent's proprietary transkingdom RNAi technology, is poised to enter phase I testing this quarter. The company said the toxicology work, which is being conducted in non-human primates, will lay the groundwork for a phase II study to begin in 2011.